Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warning To Skin Care Firm Shows Perils Of Cosmetics-To-OTC Transition

This article was originally published in The Tan Sheet

Executive Summary

FDA's warning letter saying skin care product firm MW Laboratories marketed unapproved new drugs illustrates the potentially perilous transition from offering cosmeceuticals to marketing OTC drugs

You may also be interested in...



FDA Cedes To Marketplace As Personal Care Sector Enforcer – Attorney

FDA is “letting the marketplace now scrutinize product label claims to determine whether they’re false or misleading,” Arent Fox partner Georgia Ravitz suggests based on an uptick in consumer class actions targeting personal care product claims and a lull in enforcement action in the sector since 2012.

FDA Cedes To Marketplace As Personal Care Sector Enforcer – Attorney

FDA is “letting the marketplace now scrutinize product label claims to determine whether they’re false or misleading,” Arent Fox partner Georgia Ravitz suggests based on an uptick in consumer class actions targeting personal care product claims and a lull in enforcement action in the sector since 2012.

Class-Actions Increasing As Fallout From Regulatory Action

Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics. Speakers provided examples and tips for staying out of court.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel